Highlights Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Equities

GHDN

US10501E2019

Market Closed - Deutsche Boerse AG Other stock markets 07:14:27 31/05/2024 BST			5-day change	1st Jan Change
0.475 ^EUR	+1.06%		-9.52%	+106.52%

05-20	BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn	CI
05-14	Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn	05-20	CI
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS	04-09	CI
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	02-23	CI
Brainstorm Cell Therapeutics Shares Rise on Grants, Allowance of Patent Applications	12-26	MT
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS	12-07	CI
Brainstorm Cell Says FDA Grants Meeting for Confirmatory Late-Stage Trial for NurOwn in Amyotrophic Lateral Sclerosis	11-20	MT
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS	24/10/23	CI
Brainstorm Cell Says US FDA's Advisory Panel Voted ALS Therapy NurOwn Did Not Show 'Substantial Evidence of Effectiveness'	28/09/23	MT
US FDA panel votes against BrainStorm's ALS therapy	27/09/23	RE
Brainstorm Cell Stock Trading Halted as FDA Panel Reviews Biologics License Application for NurOwn	27/09/23	MT
Brainstorm Cell Therapeutics Shares Fall After US FDA Reviewers Raise Concerns Over Safety, Efficacy of ALS Therapy	25/09/23	MT
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy	25/09/23	RE
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair	21/06/23	CI
BrainStorm Cell Therapeutics Says US FDA Advisory Panel to Review NurOwn Biologics License Application on Sept. 27	06/06/23	MT
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Equities

GHDN

US10501E2019

Highlights

Filters